Kim Junuk, Cheong Jae Ho, Hyung Woo Jin, Shen Jianguo, Choi Seung Ho, Noh Sung Hoon
Department of Surgery, Yonsei University College of Medicine, Seoul 120-752, Korea.
J Surg Oncol. 2004 Oct 1;88(1):9-13. doi: 10.1002/jso.20130.
Patients with pN3 gastric cancer are classified as having a stage IV disease just by virtue of having more than 15 metastatic lymph nodes according to the 5th UICC cancer staging criteria. We tried to verify whether the pN3 gastric cancer patients truly constitute a homogeneous group with the same poor prognosis by looking for predictors of long-term survival within the group.
Medical records of 347 patients who had gastrectomy with D2/D3 lymph node dissection for gastric cancer and diagnosed with pN3 disease by pathology, between January 1987 and December 1997 were reviewed. Clinicopathologic prognostic variables were evaluated as predictors of long-term survival by univariate and multivariate analysis.
The overall 5-year survival rate was 13.0% (95% CI, 9.3-16.6%). The extent of gastric resection and metastatic lymph node ratio were significant independent predictors of long-term survival on multivariate analysis. The 5-year survival rates for the subtotal and total gastrectomy groups were 18.2 and 8.8%, respectively. The 5-year survival rate according to the metastatic lymph node ratio was 20.2, 8.9, and 1.9% when the ratio was <0.33, 0.33-0.67, and > 0.67, respectively.
Patients with pN3 gastric cancer appear to be a heterogeneous group with clinicopathologic predictors that identify subgroups with significantly different long-term prognoses. The metastatic lymph node ratio may serve as a valuable tool to predict the long-term prognosis of these patients.
根据第5版国际抗癌联盟(UICC)癌症分期标准,pN3期胃癌患者仅因有超过15个转移淋巴结就被归类为IV期疾病。我们试图通过寻找该组内长期生存的预测因素,来验证pN3期胃癌患者是否真的构成一个预后同样不良的同质群体。
回顾了1987年1月至1997年12月间347例行胃癌D2/D3淋巴结清扫胃切除术且经病理诊断为pN3期疾病患者的病历。通过单因素和多因素分析评估临床病理预后变量作为长期生存的预测因素。
总体5年生存率为13.0%(95%可信区间,9.3 - 16.6%)。多因素分析显示,胃切除范围和转移淋巴结比例是长期生存的显著独立预测因素。胃次全切除组和全胃切除组的5年生存率分别为18.2%和8.8%。根据转移淋巴结比例,当比例<0.33、0.33 - 0.67和>0.67时,5年生存率分别为20.2%、8.9%和1.9%。
pN3期胃癌患者似乎是一个异质群体,存在临床病理预测因素可识别长期预后显著不同的亚组。转移淋巴结比例可能是预测这些患者长期预后的一个有价值的工具。